Ubix Therapeutics Joins Johnson & Johnson Innovation – JLABS

Ubix Therapeutics, Inc., a clinical-stage biotechnology company based in Seoul, South Korea, has announced its acceptance into the Johnson & Johnson Innovation – JLABS (JLABS) community in Korea. JLABS is renowned for being one of the largest global networks of health incubators, dedicated to fostering early-stage innovators who are developing the next wave of healthcare solutions. Supported by Johnson & Johnson, JLABS provides its member companies with valuable experience, mentorship, partnerships, and venture connections to help accelerate their scientific endeavors.

Ubix Therapeutics specializes in the discovery and development of innovative oncology therapeutics, utilizing Targeted Protein Degradation (TPD) technology. This approach involves leveraging the body’s natural protein degradation processes to eliminate diseased proteins, effectively shutting down disease-causing pathways. The company is currently advancing a phase 1 clinical trial for UBX-303-1, an oral small molecule degrader aimed at treating B cell malignancies. Furthermore, in July, Ubix entered into a license agreement with Yuhan Corporation, granting them the rights to develop and commercialize UBX-103, a prostate cancer drug candidate.

The inclusion of Ubix Therapeutics into the JLABS community is seen as a significant milestone for the company. CEO BK Seo expressed optimism about the opportunities this membership brings, particularly in accelerating the company’s research and development efforts. The company plans to leverage this membership to advance its pipeline, including UBX-106, a SHP2 degrader program that is set to enter IND-enabling studies. Additionally, Ubix aims to strengthen its global partnerships through this association.

Ubix Therapeutics boasts a proprietary TPD platform technology known as Degraducer®. This technology harnesses the body’s own protein degradation machinery to target and degrade diseased proteins, leading to a near-complete inactivation of harmful pathways. The company’s current pipeline includes several promising candidates. UBX-303-1 is being developed for treating relapsed or refractory B cell malignancies, while UBX-106 is aimed at MAPK signaling-dependent cancers. Beyond these, Ubix is also working on multiple preclinical and research-stage degrader assets in the fields of targeted and immuno-oncology.

The company’s acceptance into JLABS is expected to facilitate significant advancements in their research and development initiatives. By being part of this esteemed incubator network, Ubix Therapeutics can access a wealth of resources and expertise, which is critical for the progression of their innovative therapies. This strategic move aligns with the company’s mission to develop groundbreaking treatments that harness the power of TPD technology.

Ubix Therapeutics remains committed to its goal of discovering and developing new therapeutic solutions for oncology. With the support of JLABS and its expanded network, the company is well-positioned to make substantial progress in its pipeline projects and to forge new collaborations that will drive the future of cancer treatment.